Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.

ABSTRACT:

Background

Prostate cancer (PCa) is one of the most frequently occurring malignancies. Although most cases are not life-threatening, approximately 20% endure an unfavorable outcome. PSA-based screening reduced mortality but at the cost of an increased overdiagnosis/overtreatment of low-risk (lrPCa) and favorable intermediate-risk (firPCa) PCa. PCa risk-groups are usually identified based on serum Prostate-Specific Antigen (PSA), the Gleason score, and clinical T stage, which have consistent although variable specificity or subjectivity. Thus, more effective and specific tools for risk assessment are needed, ideally making use of minimally invasive methods such as liquid biopsies. In this systematic review we assessed the clinical potential and analytical performance of liquid biops

SUBMITTER: Sequeira JP 

PROVIDER: S-EPMC11011064 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature